Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. (2017)
Attributed to:
EPICure@19 - the extremely preterm young adult
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1474-4422(17)30113-8
PubMed Identifier: 28600189
Publication URI: http://europepmc.org/abstract/MED/28600189
Type: Journal Article/Review
Volume: 16
Parent Publication: The Lancet. Neurology
Issue: 8
ISSN: 1474-4422